NexoBrid ® is a topically administered biological orphan drug that enzymatically removes eschar while preserving viable ...

MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns, the peer-reviewed Journal of the ...

MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

In one case, black salve corroded a man’s whole nose. It had to be amputated. In 2018, an Australian woman called Helen ...

MediWound's first drug, NexoBrid ®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for ...

Learn more about whether PTC Therapeutics, Inc. or Vericel Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Valeo Financial Advisors LLC cut its stake in Vericel Co. (NASDAQ:VCEL – Free Report) by 19.7% during the 4th quarter, ...

After hours: February 21 at 6:16:18 PM EST Loading Chart for VCEL ...

MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced ...

MediWound currently markets NexoBrid which is approved for eschar removal in adult and pediatric patients with deep partial thickness and/or full thickness thermal burns in several geographies ...